Literature DB >> 28894583

Evaluation of treatment for rectal neuroendocrine tumors sized under 20 mm in comparison with the WHO 2010 guidelines.

Nobuhisa Matsuhashi1, Takao Takahashi1, Hiroyuki Tomita2, Hiroshi Araki3, Takashi Ibuka3, Kaori Tanaka1, Toshiyuki Tanahashi1, Satoshi Matsui1, Yoshiyuki Sasaki1, Yoshihiro Tanaka1, Naoki Okumura1, Kazuya Yamaguchi1, Shinji Osada1, Kazuhiro Yoshida1.   

Abstract

Rectal neuroendocrine tumor (NET) is a relatively rare lesion of the gastrointestinal tract, but the prospective examination with colonofiberoscopy or endoscopic ultrasound has increased the frequency of its detection. It is often difficult to determine the optimal treatment for NETs sized <20 mm in the clinical setting. Other clinicopathological variables are not considered in the current guidelines and staging systems. Although the effects of lymphovascular invasion are not covered by the World Health Organization (WHO) 2010 guidelines or tumor-node-metastasis (TNM) staging system, this may be promising for the establishment of improved guidelines and staging systems, particularly for early-stage colorectal carcinoids. The aim of the present study was to evaluate rectal NETs sized <20 mm in comparison with the WHO 2010 guidelines. Between January 2005 and December 2013, 40 consecutive patients [26 men and 14 women; median age, 59.3 years (range, 34-81 years)] who underwent endoscopic resection of rectal NETs, and 12 patients undergoing surgical resection of rectal NETs, were enrolled in this retrospective study. The median tumor size was 7.4 mm (range, 3-15 mm). The locations of the NET were the rectosigmoid colon (n=3), the upper rectum (n=13), and the lower rectum (n=25). The NETs were classified by size as 0-5 (n=7), 6-10 (n=29) and 11-15 mm (n=4). The surgical procedures performed included low anterior resection plus esophagectomy (n=1), laparoscopic low anterior resection (n=7) and laparoscopic intersphincteric resection (n=4). Only 1 patient had lymph node metastasis (tumor sized 6-10 mm, with lymphovascular invasion). NET recurrence was not detected in any of the patients. According to the WHO guidelines, the tumors were classified as grade (G)1 (n=8), G2 (n=3) and G1/G2 (n=1). The tumor in the patient with lymph node metastasis was G1. NETs sized <10 mm may be curatively treated by endoscopic resection. However, NETs with either lymphovascular invasion or sized >1 cm carry a risk for metastasis equivalent to that of adenocarcinomas. Therefore, it is mandatory to histologically examine lymphovascular invasion in specimens retrieved via endoscopic resection to determine the necessity for further radical surgery with regional lymph node dissection. The treatment of NETs sized <20 mm as presently defined in the WHO 2010 guidelines requires further evaluation.

Entities:  

Keywords:  World Health Organization 2010 guidelines; rectal neuroendocrine tumor; size under 20 mm

Year:  2017        PMID: 28894583      PMCID: PMC5582451          DOI: 10.3892/mco.2017.1326

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  22 in total

1.  A pilot randomized control study to evaluate endoscopic resection using a ligation device for rectal carcinoid tumors.

Authors:  Hiroyuki Sakata; Ryuichi Iwakiri; Akifumi Ootani; Seiji Tsunada; Shinichi Ogata; Hibiki Ootani; Ryo Shimoda; Kanako Yamaguchi; Yasuhisa Sakata; Sadahiro Amemori; Kotaro Mannen; Masanobu Mizuguchi; Kazuma Fujimoto
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

Review 2.  Carcinoids of the rectum: an evaluation of 1271 reported cases.

Authors:  J Soga
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

3.  Lymph-node metastases in rectal carcinoids.

Authors:  Yoshiya Fujimoto; Masatoshi Oya; Hiroya Kuroyanagi; Masashi Ueno; Takashi Akiyoshi; Toshiharu Yamaguchi; Tetsuichiro Muto
Journal:  Langenbecks Arch Surg       Date:  2008-12-02       Impact factor: 3.445

Review 4.  The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.

Authors:  Günter Klöppel; Aurel Perren; Philipp U Heitz
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

Review 5.  Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.

Authors:  Eduardo Vilar; Ramón Salazar; Jose Pérez-García; Javier Cortes; Kjell Oberg; Josep Tabernero
Journal:  Endocr Relat Cancer       Date:  2007-06       Impact factor: 5.678

6.  Endocrinocarcinomas (carcinoids and their variants) of the duodenum. An evaluation of 927 cases.

Authors:  J Soga
Journal:  J Exp Clin Cancer Res       Date:  2003-09

7.  Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade.

Authors:  Tadashi Hasegawa; Yoshihiro Matsuno; Tadakazu Shimoda; Setsuo Hirohashi
Journal:  Hum Pathol       Date:  2002-06       Impact factor: 3.466

8.  Saline-assisted endoscopic resection of rectal carcinoids: cap aspiration method versus simple snare resection.

Authors:  T Nagai; R Torishima; H Nakashima; H Ookawara; A Uchida; S Kai; R Sato; K Murakami; T Fujioka
Journal:  Endoscopy       Date:  2004-03       Impact factor: 10.093

9.  Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors.

Authors:  Tetsuhide Ito; Masao Tanaka; Hironobu Sasano; Yoshiyuki R Osamura; Iwao Sasaki; Wataru Kimura; Koji Takano; Takao Obara; Miyuki Ishibashi; Kazuwa Nakao; Ryuichiro Doi; Akira Shimatsu; Toshirou Nishida; Izumi Komoto; Yukio Hirata; Masayuki Imamura; Ken Kawabe; Kazuhiko Nakamura
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 6.772

10.  Clinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence.

Authors:  Takeshi Yamaguchi; Takahiro Fujimori; Shigeki Tomita; Kazuhito Ichikawa; Hiroyuki Mitomi; Kazuya Ohno; Yosuke Shida; Hiroyuki Kato
Journal:  Diagn Pathol       Date:  2013-04-22       Impact factor: 2.644

View more
  4 in total

Review 1.  Management of Gastrointestinal Neuroendocrine Tumors.

Authors:  Rongzhi Wang; Rui Zheng-Pywell; H Alexander Chen; James A Bibb; Herbert Chen; J Bart Rose
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-10-24

2.  Risk Factors for Lymph Node Metastasis and Oncologic Outcomes in Small Rectal Neuroendocrine Tumors with Lymphovascular Invasion.

Authors:  Seung-Joo Nam; Byung Chang Kim; Hee Jin Chang; Han Ho Jeon; Junho Kim; Su Young Kim
Journal:  Gut Liver       Date:  2022-03-15       Impact factor: 4.519

Review 3.  Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance.

Authors:  Camilla Gallo; Roberta Elisa Rossi; Federica Cavalcoli; Federico Barbaro; Ivo Boškoski; Pietro Invernizzi; Sara Massironi
Journal:  World J Gastroenterol       Date:  2022-03-21       Impact factor: 5.742

4.  Rectal neuroendocrine tumor developing lateral lymph node metastasis after curative resection: a case report.

Authors:  Yoshihisa Tokumaru; Nobuhisa Matsuhashi; Takao Takahashi; Hisashi Imai; Yoshihiro Tanaka; Naoki Okumura; Kazuya Yamaguchi; Kazuhiro Yoshida
Journal:  World J Surg Oncol       Date:  2020-04-13       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.